Latest Breaking News On - Therapeutic equivalence evaluations - Page 20 : comparemela.com

Theravance Biopharma, Inc Reports Third Quarter 2022 Financial Results, Provides Business Update and Extends Tender Offer

Reported another record quarter of YUPELRI® (revefenacin) net sales and profitability: $18.7 million Q3 2022 sales up 35% from Q3 2021 (TBPH implied 35%.

New yorkUnited statesRicke winninghamTheravance biopharmaAndrew hindmanComputershare trust companyCompany offer to purchaseMillion capital return programInternational symposiumDrug administrationTheravance biopharma incCompany annual report on formCompany formDevelopment rd expensesTheravance respiratory companySecurities exchange

Acer Therapeutics Receives Notice of Allowance of Key US Patent Application Covering EDSIVO™ (celiprolol)

Acer Therapeutics Receives Notice of Allowance of Key US Patent Application Covering EDSIVO™ (celiprolol)
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

France generalAcer contactscorporateJeff davisTruven marketscanAcer therapeutics incJournal of american college cardiologyTrademark officeJim denikeacer therapeutics incExchange commissionNick colangelogilmartin groupLassistance publiqueProviding celiprolol therapyDecentralized studyEvent reductionChief business officerLong term observational study

Patents: a necessary evil?

Dave Elder explores US patent developments amid growing concerns that current approaches may delay generic drugs and biosimilars entering the market.

United statesUnited kingdomCity ofDave elderActa pharmaceutica sinicaSanta clara high technology law journalDrug administrationBiopharmaceutical research developmentCato instituteTrademark officeBiotech companiesNational bureau of economicAnalysis groupKing collegeOrange bookJoint pharmaceutical analysis group

Mylan Failed to Immediately Envisage the Compounds in Merck s Patent Covering Januvia | Haug Partners LLP

In Mylan Pharm. Inc. v. Merck Sharp & Dohme Corp., the Federal Circuit considered whether prior disclosure of a genus of compounds and their pharmaceutically acceptable salts was.

Mylan pharmMerck januviaCourt judges lourieMerck sharp dohme corpMerck sharpDohme corpFederal circuitJudges lourieDrug productsTherapeutic equivalence evaluations

Merck Sues Gland Pharma for Patent Infringement in ANDA Suit

A suit was filed on Thursday in the District of New Jersey by plaintiff Merck Sharp & Dohme LLC (Merck) against defendant Gland Pharma Limited

United statesNew jerseyTrademark officeGland pharma limitedMerck sharp dohmeCourt merckDunn crutcherMerck sharpDrug productsTherapeutic equivalence evaluationsOrange bookIntravenous solution formulations stabilizedSubstituted beta cyclodextrinUnited states patentGeneric posaconazole